ZURICH, Sept 17 (Reuters) – Novartis’s
investigational multiple sclerosis drug cut the risk of
disability progression in patients with a tough-to-treat form of
the disease versus a placebo, the…
The post UPDATE 1-Novartis says MS drug cut risk of disability advance in study appeared first on NASDAQ.